AKTS is ready to breakoutIntraday trade idea for AKTS
Oversold stock with positive news.
Extreme Value Sniper Divergence on H1 Chart.
Breakout and target levels are on the chart.
Long
Aktis Oncology, Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−63.73 M USD
6.50 M USD
29.26 M
About Aktis Oncology, Inc.
Sector
Industry
CEO
Matthew Roden
Website
Headquarters
Boston
Founded
2020
IPO date
Jan 9, 2026
IPO offer price
18.00 USD
Identifiers
3
ISIN US01021M1045
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.
Related stocks
Long
AKTS is a buy for meI think we can go lower BUT we might get a 30% gain before that!!
NOT FINANCIAL ADVICE!!!!
AKTS: Potential BuyPrice has broken above the Ichimoku cloud which hasn't happened in a long time. RSI bullish. First target around 1 USD pschological level. Long term target 3 USD.
Long
LONG AKTS 20+% returnsNASDAQ:AKTS Akoustis Technologies positive momentum 27% median returns in the past
Long
Looks pretty good, right? 🎃Hi folks, Yurii Domaranskyi here. Let's take a look at the chart.
We have a local low,
sharp approach to the level on daily and 5 minutes timeframes,
once the level was broken down, the price tested it once, when it tested it for the second time and a 5m bar closed above the level 5.70$ I got a pos
Long
$AKTS Akoustis tech Inc Potential Weekly Breakout
Hopefully you find the chart helpful in terms of Supports & Resistance etc.
we refrain from adding commentary on the chart as that is reserved for our members and we are very conscious of not giving financial or trading advice.
Thank you for taking time to consult our chart and we would really a
Long
Short squeeze mini series # 17What Is a Short Squeeze?
A short squeeze occurs when a stock or other
asset jumps sharply higher, forcing traders who
had bet that its price would fall, to buy it in
order to forestall even greater losses. Their
scramble to buy only adds to the upward
pressure on the stock's price
KEY TAKEAWAYS
*A
MULTI YEAR RESISTANCE BREAKOUT As you can see, this stock has been hitting a wall at the 9.00-9.50 range for over a year now. It finally broke out. First target is 12.50-13.00 range.
Long
Akoustis Awarded New DARPA Contract to Advance XBAW Technology!!AKTS: Akoustis, Inc.
2020-10-27 07:00:10
Akoustis Awarded New DARPA Contract to Advance XBAW Technology
Long
Long
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently asked questions
The current price of AKTS is 18.60 USD — it has decreased by −1.27% in the past 24 hours. Watch Aktis Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aktis Oncology, Inc. stocks are traded under the ticker AKTS.
AKTS stock has fallen by −2.05% compared to the previous week, the month change is a 7.95% rise, over the last year Aktis Oncology, Inc. has showed a −17.15% decrease.
We've gathered analysts' opinions on Aktis Oncology, Inc. future price: according to them, AKTS price has a max estimate of 34.00 USD and a min estimate of 30.00 USD. Watch AKTS chart and read a more detailed Aktis Oncology, Inc. stock forecast: see what analysts think of Aktis Oncology, Inc. and suggest that you do with its stocks.
AKTS reached its all-time high on Jan 12, 2026 with the price of 24.50 USD, and its all-time low was 14.72 USD and was reached on Mar 30, 2026. View more price dynamics on AKTS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AKTS stock is 3.91% volatile and has beta coefficient of 2.76. Track Aktis Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aktis Oncology, Inc. there?
Yes, you can track Aktis Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Aktis Oncology, Inc. is going to release the next earnings report on Jun 3, 2026. Keep track of upcoming events with our Earnings Calendar.
AKTS earnings for the last quarter are −9.72 USD per share, whereas the estimation was −21.59 USD resulting in a 54.98% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Aktis Oncology, Inc. earnings.
Aktis Oncology, Inc. revenue for the last quarter amounts to 1.87 M USD, despite the estimated figure of 3.28 M USD. In the next quarter, revenue is expected to reach 1.75 M USD.
AKTS net income for the last quarter is −15.14 M USD, while the quarter before that showed −12.06 M USD of net income which accounts for 0.00% change. Track more Aktis Oncology, Inc. financial stats to get the full picture.
No, AKTS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 9, 2026, the company has 79 employees. See our rating of the largest employees — is Aktis Oncology, Inc. on this list?
Like other stocks, AKTS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aktis Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.